Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT

Description

Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of non-investigational, standard-of-care, combined chemotherapy and radiation therapy (CCRT) and to develop and assess predictive models for CRF severity.

Conditions

Cancer, Thoracic Cancer, Gynecologic Cancer, Head and Neck Cancer, Gastrointestinal Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of non-investigational, standard-of-care, combined chemotherapy and radiation therapy (CCRT) and to develop and assess predictive models for CRF severity.

An Evaluation of Changes in the Relationships Between Fatigue and Molecular Mechanisms in Cancer Patients Receiving Curative-Intent Combined Chemotherapy and Radiation Therapy (CCRT)

Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT

Condition
Cancer
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants have not received any prior treatment (i.e., cancer systemic therapies or radiation therapy) in the past year except surgery.
  • * Participants receiving \>= 15 fractions.
  • * Participants is male or female and is \>18 years of age on the day of signing the informed consent.
  • * Ability to understand a written informed consent document.
  • * Able and willing to complete all of the study questionnaires and provide blood and stool samples prior to, midway, and following the completion of treatment.
  • * Willing to have medical records reviewed for clinical information.
  • * Able to read, write and understand English or Spanish.
  • * Contraindication to phlebotomy for removal of approximately 50 mL of peripheral blood within 6 week period (Institutional Review Board (IRB) limit).

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Francisco,

Sue Yom, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2027-09-01